BR0008963A - Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos - Google Patents

Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos

Info

Publication number
BR0008963A
BR0008963A BR0008963-0A BR0008963A BR0008963A BR 0008963 A BR0008963 A BR 0008963A BR 0008963 A BR0008963 A BR 0008963A BR 0008963 A BR0008963 A BR 0008963A
Authority
BR
Brazil
Prior art keywords
ige
domain
epsilon
epitopes
antagonists
Prior art date
Application number
BR0008963-0A
Other languages
English (en)
Inventor
Michael Dyson
Martin Friede
Judith Greenwood
Ellen Hewitt
Lan Lamont
Sean Mason
Roger Randall
William Gordon Turnell
Arcelle Paulette Van Mechelen
Carlota Vinals Y De Bassols
Original Assignee
Smithkline Beecham Biolog
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Smithkline Beecham Biolog, Peptide Therapeutics Ltd filed Critical Smithkline Beecham Biolog
Publication of BR0008963A publication Critical patent/BR0008963A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: "EPìTOPOS OU MIMóTOPOSDERIVADOS DO DOMìNIO DE C-EPSILON-2 DE IGE,ANTAGONISTAS DESTES, E SEUS USOS TERAPêUTICOS". Apresente invenção refere-se à provisão de novos medicamentospara o tratamento, prevenção ou melhora de doença alérgica. Emparticular, os novos medicamentos são peptídeos isoladosincorporando os epítopos ou mimótopos de regiões expostas nasuperfície do domínio C<sym>2 de IgE. Os inventores constataramque estas novas regiões podem ser o alvo para igualmenteimunoterapia ou imunoprofilaxia passiva e ativa. A invenção aindarefere-se a métodos para a produção dos medicamentos,composições farmacêuticas contendo-os e seu uso em medicina.Também formando um aspecto da presente invenção estão osligandos, especialmente anticorpos monoclonais, que são capazesde ligarem-se às regiões de IgE expostos na superfície da presenteinvenção, e seu uso em medicina como imunoterapia passiva ouem imunoprofilaxia.
BR0008963-0A 1999-02-25 2000-02-22 Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos BR0008963A (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody
PCT/EP2000/001455 WO2000050460A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Publications (1)

Publication Number Publication Date
BR0008963A true BR0008963A (pt) 2001-11-27

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008963-0A BR0008963A (pt) 1999-02-25 2000-02-22 Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos

Country Status (19)

Country Link
EP (1) EP1155037A1 (pt)
JP (1) JP2004538238A (pt)
KR (1) KR20020007313A (pt)
CN (1) CN1348466A (pt)
AR (1) AR029336A1 (pt)
AU (1) AU2672700A (pt)
BR (1) BR0008963A (pt)
CA (1) CA2363637A1 (pt)
CO (1) CO5210906A1 (pt)
CZ (1) CZ20013082A3 (pt)
HK (1) HK1044004A1 (pt)
HU (1) HUP0200049A2 (pt)
IL (1) IL145024A0 (pt)
MX (1) MXPA01008613A (pt)
NO (1) NO20014130L (pt)
NZ (1) NZ513679A (pt)
PL (1) PL350993A1 (pt)
TR (1) TR200102506T2 (pt)
WO (1) WO2000050460A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
JP4229704B2 (ja) * 2001-04-18 2009-02-25 ダイアックス、コープ Ｆｃ領域ポリペプチドの結合分子
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
AR065368A1 (es) * 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP2010519194A (ja) * 2007-02-15 2010-06-03 アストラゼネカ・アクチエボラーグ ＩｇＥ分子に対する結合要素
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
EP3882274A4 (en) * 2018-09-21 2022-06-29 Riken Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
EP0996857B1 (en) * 1997-07-17 2009-09-09 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides

Also Published As

Publication number Publication date
PL350993A1 (en) 2003-02-24
HUP0200049A2 (en) 2002-05-29
IL145024A0 (en) 2002-06-30
AU2672700A (en) 2000-09-14
WO2000050460A1 (en) 2000-08-31
TR200102506T2 (tr) 2002-06-21
KR20020007313A (ko) 2002-01-26
CZ20013082A3 (cs) 2002-02-13
JP2004538238A (ja) 2004-12-24
MXPA01008613A (es) 2003-06-24
NZ513679A (en) 2001-09-28
NO20014130D0 (no) 2001-08-24
CA2363637A1 (en) 2000-08-31
EP1155037A1 (en) 2001-11-21
NO20014130L (no) 2001-09-13
CO5210906A1 (es) 2002-10-30
HK1044004A1 (zh) 2002-10-04
AR029336A1 (es) 2003-06-25
CN1348466A (zh) 2002-05-08

Similar Documents

Publication Publication Date Title
Mandal et al. Targeting CDK9 for anti-cancer therapeutics
DE69931377T2 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
Faurant From bark to weed: the history of artemisinin
Rehman et al. Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis
Choi et al. Podophyllotoxin acetate triggers anticancer effects against non-small cell lung cancer cells by promoting cell death via cell cycle arrest, ER stress and autophagy
NO20014131L (no) Epitoper eller mimotoper avledet fra C-epsilon-3- eller C- epsilon-4-domener fra IgE, antagonister derav og deresterapeutiske anvendelser
Qi et al. Arctigenin attenuates learning and memory deficits through PI3k/Akt/GSK-3β pathway reducing tau hyperphosphorylation in Aβ-induced AD mice
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
Dong et al. Targeting the interplay of autophagy and ROS for cancer therapy: An updated overview on phytochemicals
Gooshe et al. The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes
Das et al. Promise of the NLRP3 inflammasome inhibitors in in vivo disease models
BR0008963A (pt) Epìtopos ou mimótopos derivados do domìnio dec-epsilon-2 de ige, antagonistas destes, e seususos terapêuticos
ES2908141T3 (es) Formulaciones y dosis de cannabinoides
Bharate et al. Discovery and preclinical development of IIIM-160, a Bergenia ciliata-based anti-inflammatory and anti-arthritic botanical drug candidate
BR112019002655A2 (pt) composto, intermediário de síntese, uso e composição farmacêutica neuromoduladora
RU2019113989A (ru) Лекарственное средство
Wollina Peat: a natural source for dermatocosmetics and dermatotherapeutics
Bussing et al. Pharmacokinetics of monoclonal antibody and antibody fragments in the mouse eye following systemic administration
Jaafari et al. Targeting of liposomes to melanoma cells with high levels of ICAM‐1 expression through adhesive peptides from immunoglobulin domains
BR0008964A (pt) Epìtopos ou mimótopos derivados dos campos dec-epsilon-3 ou c-epsilon-4 de ige, antagonistas dosmesmos e seus usos terapêuticos
BRPI0621416A2 (pt) composição para o tratamento de doenças bacterianas, virais, fúngicas, inflamação e dor
WO2002034288A3 (en) Vaccine for treating allergy
Szuster-Ciesielska et al. Immunogenic Evaluation of Ribosomal P‐Protein Antigen P0, P1, and P2 and Pentameric Protein Complex P0‐(P1‐P2) 2 of Plasmodium falciparum in a Mouse Model
JP5836968B2 (ja) ＩｇＥ媒介性疾患の処置方法
Ushkalova et al. Sodium metamizole: regulatory status around the world, safety problems and medication errors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.